1. Cutaneous Toxicities With Amivantamab for Non-Small Cell Lung Cancer: A Practical Guide and Best Practices.
- Author
-
Singh-Kandah S, Wang K, Xia K, Lain Johnson A, D'Andrea DM, Shu CA, Bray Dougherty L, and Gallitano SM
- Subjects
- Humans, Female, Middle Aged, Male, Aged, Adult, Aged, 80 and over, Paronychia chemically induced, Paronychia drug therapy, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Practice Guidelines as Topic, Drug Eruptions etiology, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Background: Amivantamab is an epidermal growth factor receptor (EGFR) and MET bispecific antibody approved for certain patients with advanced non-small cell lung cancer with EGFR variant. Cutaneous toxicities are known on-target effects of EGFR inhibition., Objectives: This article describes the occurrence and management of cutaneous toxicities in patients whose disease progressed on platinum chemotherapy treated with amivantamab., Methods: Post hoc analysis evaluated incidence, severity, and time to first onset of rash and paronychia. Five nurses and advanced practice providers were interviewed., Findings: Of 380 patients, 296 (78%) experienced treatment-related rash and/or paronychia. Paronychia (43%), rash (36%), and dermatitis acneiform (35%) were most frequent, with scalp rash reported by 17%. Treatment modifications because of rash and paronychia were infrequent. Nurses and advanced practice providers collaborate with physicians to manage cutaneous toxicities by administering comedications, modifying amivantamab dose, and educating patients.
- Published
- 2024
- Full Text
- View/download PDF